Patricia Cruite
About Patricia Cruite
Patricia Cruite is a scientist currently employed at Sana Biotechnology, Inc. in Cambridge, MA, where she has worked since 2019. She holds a Master of Science in Biochemistry from The University of Texas at Austin and has extensive experience in gene therapy research.
Work at Sana Biotechnology
Patricia Cruite has been employed at Sana Biotechnology, Inc. as a Scientist since 2019. In her role, she has designed and performed in vitro screens for gene therapy vectors. Additionally, she established a suite of characterization assays for recombinant proteins and developed specificity assays tailored for Sana's gene therapy platform. Cruite also supervises and trains a principal research associate, contributing to the development of innovative solutions in gene therapy.
Education and Expertise
Patricia Cruite earned her Master of Science (MS) in Biochemistry from The University of Texas at Austin, where she studied from 2007 to 2010. Prior to that, she completed her Bachelor of Science (BSc) in Biochemistry at Case Western Reserve University from 2003 to 2007. Her educational background provides a strong foundation for her work in the biotechnology sector, particularly in gene therapy and recombinant protein characterization.
Background
Before joining Sana Biotechnology, Patricia Cruite worked at Adimab, LLC in various roles from 2011 to 2019. She began as a Research Associate II and progressed to Principal Research Associate II, where she spent four years. Her experience at Adimab included engineering lead constructs for improved potency or specificity in gene therapy applications and establishing characterization assays for recombinant proteins.
Professional Experience at Adimab, LLC
Patricia Cruite's tenure at Adimab, LLC spanned several years, during which she held multiple positions. She served as an Associate Scientist from 2018 to 2019, and prior to that, she was a Principal Research Associate II from 2014 to 2018. She also worked as a Principal Research Associate I in 2012 and as a Research Associate II in 2011. Her roles involved significant contributions to gene therapy research and development.